A Study of MRG002 in the Treatment of HER2-positive Unresectable Locally Advanced or Metastatic Urothelium Cancer

• Status: Recruiting
• Trial end date: 2022-09-01
• Target enrollment: 0
• Participant gender: All

Summary

The objective of this study is to assess the safety, efficacy, pharmacokinetics, and immunogenicity of MRG002 as single agent in patients with HER2-positive unresectable locally advanced or metastatic urothelium cancer.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Shanghai Miracogen Inc.

Criteria

Inclusion Criteria:

1. Willing to sign the ICF and follow the requirements specified in the protocol.

2. Aged 18 to 75 (including 18 and 75), both genders.

3. Expected survival time ≥ 12 weeks.

4. Patients with unresectable locally advanced or metastatic urothelium cancer confirmed by histopathology.

5. Failed in the prior one or more line of systemic chemotherapy.

6. HER2 positive (IHC 3 + or IHC 2 +) in the tumor specimens confirmed by central laboratory test.

7. Archival or biopsy tumor specimens should be provided (primary or metastatic).

8. Patients must have measurable lesions according to the Response Evaluation Criteria in Solid Tumors (RECIST v1.1).

9. ECOG performance score 0 or 1.

10. Prior anti-tumor treatment-related AEs (NCI CTCAE v5.0 Criteria) have recovered to ≤ Grade 1 (except alopecia, non-clinically significant or asymptomatic laboratory abnormalities).

11. No severe cardiac dysfunction with left ventricular ejection fraction (LVEF) ≥ 50%.

12. Organ function must meet the basic requirements.

13. Coagulation function must meet the basic requirements.

14. Patients of childbearing potential must take effective contraceptive measures during the treatment and for 6 months after the last dose of treatment.

Exclusion Criteria:

1. History of hypersensitivity to any component of MRG002 or history of hypersensitivity of ≥ Grade 3 to trastuzumab.

2. Received radiotherapy, chemotherapy, biotherapy, immunotherapy, or other anti-tumor drugs within 4 weeks prior to the first dose MRG002 treatment.

3. Patients with clinical symptoms such as pleural, abdominal or pericardial effusion requiring puncture drainage.

4. Patients with central nervous system (CNS) metastasis and/or neoplastic meningitis.

5. Any severe or uncontrolled systemic diseases.

6. Patients with poorly controlled heart diseases.

7. Evidence of active infections, including but not limited to Hepatitis B, Hepatitis C, or human immunodeficiency virus (HIV) infection.

8. History of other primary malignancies.

9. History of interstitial pneumonia, severe chronic obstructive pulmonary disease, severe pulmonary insufficiency, symptomatic bronchospasm, etc.

10. Peripheral neuropathy greater than Grade 1.

11. History of cirrhosis (decompensated cirrhosis Child-Pugh class B and C).

12. Patients with active autoimmune disease or a history of autoimmune disease, who are using immunosuppressive agents, or systemic hormone therapy and still receiving within 2 weeks prior to enrollment.

13. Received anti-tumor vaccine treatment 4 weeks prior to the first dose or planning to participate in anti-tumor vaccine trials.

14. Female patents with a positive serum pregnancy test or who are breast-feeding or who do not agree to take adequate contraceptive measures during the treatment and for 6 months after the last dose of study treatment.

15. Other conditions inappropriate for participation in this clinical trial, at the discretion of the investigator.